Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

Specific interventions included in the review Studies of RIMAs, i.e. MOC (18 to 600 mg) or BRO (93.1 to 150 mg/day) versus either placebo or another standard tricyclic antidepressant, selective serotonin re-uptake inhibitor (SSRI) or other class of antidepressant, were included. The active comparison groups included: diazepam, tranylcypromine, mianserin, isocarboxide, imipramine, amitriptyline, fluvoxamine, viloxazine, toloxatone, dothiepin, nortriptyline, fluoxetine, and doxepin. Four classes of comparisons were reported: MOC or BRO versus placebo, and MOC or BRO versus active antidepressants. No study directly compared the antidepressant effects of MOC and BRO.